NCT02662608View on ClinicalTrials.gov

Compassionate Use of Brontictuzumab for Adenoid Cystic Carcinoma (ACC)

NACompletedINTERVENTIONAL
Enrollment

1

Participants

Timeline

Start Date

December 29, 2015

Primary Completion Date

March 6, 2016

Study Completion Date

March 6, 2016

Conditions
Adenoid Cystic Carcinoma
Interventions
DRUG

Brontictuzumab

1.5 mg/Kg intravenously every three weeks.

Trial Locations (1)

77030

University of Texas MD Anderson Cancer Center, Houston

All Listed Sponsors
lead

M.D. Anderson Cancer Center

OTHER

NCT02662608 - Compassionate Use of Brontictuzumab for Adenoid Cystic Carcinoma (ACC) | Biotech Hunter | Biotech Hunter